Top

27-09-2024 | Thrombosis | Research

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms

Authors: Mirjana Cvetković, Isidora Arsenović, Mihailo Smiljanić, Marta Sobas, Andrija Bogdanović, Danijela Leković

Abstract

Higher neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been associated with increased risk of thrombosis, cardiovascular mortality, but their role in myeloproliferative neoplasms (MPN) remains unclear. We analyzed NLR and PLR as prognostic markers for thrombosis and overall survival (OS) in the study that included 461 consecutive MPN patients who were diagnosed from 2018 to 2022 at University center. Twenty age-matched patients without hematological disorder were used as controls. NLR and PLR were significantly increased in whole MPN group compared to controls. NLR was highest in PV > PMF > ET (p < 0.001) while PLR was highest in ET > PMF > PV (p < 0.001). Thrombosis occurrence during follow-up correlated with NLR, NLR ≥ 4.5, presence of ≥ 2 CV factors and previous thrombosis. Arterial thrombosis was associated with previous thrombosis, NLR and NLR ≥ 4.5. Similarly in venous thrombosis previous thrombosis was risk factor, together with NLR, NLR ≥ 4.5, PLR, but also secondary malignancy and female gender. In multivariate Cox model, most important factors for thrombosis development during follow-up were previous thrombosis, NLR ≥ 4.5 and PLR ≥ 500; for arterial thrombosis, NLR ≥ 4.5 and previous thrombosis; for venous thrombosis PLR ≥ 500 and previous thrombosis. Patients with pre-PMF had significantly higher NLR than ET patients. In multivariate Cox regression model, most important factors associated with survival were NLR ≥ 4.5 and PLR ≥ 500. This study highlights strong prognostic correlation of NLR ≥ 4.5 and PLR ≥ 500 with development of thrombosis and OS in MPN. Besides previous thrombosis, most important factor associated with development of arterial thrombosis is NLR ≥ 4.5 and for venous PLR ≥ 500. Our results revealed that NLR ≥ 4.5 could be used as additional marker to distinguish ET from prePMF.

Ng ZY, Fuller KA, Mazza-Parton A, Erber WN (2023) Morphology of myeloproliferative neoplasms. Int J Lab Hematol 45:59–70. https://doi.org/10.1111/ijlh.14086CrossRefPubMed

Hematopoietic and lymphoid neoplasm database (2024) SEER n.d. https://seer.cancer.gov/seertools/hemelymph/ Accessed July 19

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic neoplasms. Leukemia 36(7):1703–1719. https://doi.org/10.1038/s41375-022-01613-1CrossRefPubMedPubMedCentral

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM et al (2022) International Consensus classification of myeloid neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200–1228. https://doi.org/10.1182/blood.2022015850CrossRefPubMedPubMedCentral

Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM et al (2023) The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol 98(1):166–179. https://doi.org/10.1002/ajh.26751CrossRefPubMed

O’Sullivan JM, Mead AJ, Psaila B (2023) Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. Blood 141(4):380–390. https://doi.org/10.1182/blood.2021014668CrossRefPubMed

Greenfield G, McMullin MF, Mills K (2021) Molecular pathogenesis of the myeloproliferative neoplasms. J Hematol Oncol 14(1):103. https://doi.org/10.1186/s13045-021-01116-zCrossRefPubMedPubMedCentral

Mendez Luque LF, Blackmon AL, Ramanathan G, Fleischman AG (2019) Key role of inflammation in Myeloproliferative neoplasms: Instigator of Disease initiation, progression. And symptoms. Curr Hematol Malig Rep 14(3):145–153. https://doi.org/10.1007/s11899-019-00508-wCrossRefPubMedPubMedCentral

McMullin MF, Anderson LA (2020) Aetiology of Myeloproliferative Neoplasms. Cancers (Basel) 12(7):1810. https://doi.org/10.3390/cancers12071810CrossRefPubMed

10.

Anderson LA, McMullin MF (2014) Epidemiology of MPN: what do we know? Curr Hematol Malig Rep 9(4):340–349. https://doi.org/10.1007/s11899-014-0228-zCrossRefPubMed

11.

Tremblay D, Yacoub A, Hoffman R (2021) Overview of myeloproliferative neoplasms: history, Pathogenesis, Diagnostic Criteria, and complications. Hematol Oncol Clin North Am 35(2):159–176. https://doi.org/10.1016/j.hoc.2020.12.001CrossRefPubMedPubMedCentral

12.

Hasselbalch HC (2012) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119(14):3219-25. https://doi.org/10.1182/blood-2011-11-394775

13.

Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, Andersson TML (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a Population-based Cohort Study. Ann Intern Med 168(5):317–325. https://doi.org/10.7326/m17-0028CrossRefPubMedPubMedCentral

14.

Kelliher S, Falanga A (2021) Thrombosis in myeloproliferative neoplasms: a clinical and pathophysiological perspective. Thromb Update 5(100081):100081. https://doi.org/10.1016/j.tru.2021.100081CrossRef

15.

Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778–782. https://doi.org/10.1182/blood-2009-08-238956CrossRefPubMed

16.

Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T (2019) A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer 19(1):184. https://doi.org/10.1186/s12885-019-5387-9CrossRefPubMedPubMedCentral

17.

Barbui T, Carobbio A, De Stefano V (2022) Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Haemost 6(1):e12657. https://doi.org/10.1002/rth2.12657CrossRefPubMedPubMedCentral

18.

Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224–2232. https://doi.org/10.1200/JCO.2005.07.062CrossRefPubMed

19.

Finazzi G, low-dose aspirin in polycythemia (ECLAP) (2004) A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol (Paris) 52(5):285–288. https://doi.org/10.1016/j.patbio.2004.02.007CrossRefPubMed

20.

Song M, Graubard BI, Rabkin CS, Engels EA (2021) Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Rep 11(1):464. https://doi.org/10.1038/s41598-020-79431-7CrossRefPubMedPubMedCentral

21.

Farah R, Nseir W, Kagansky D, Khamisy-Farah R (2020) The role of neutrophil-lymphocyte ratio, and mean platelet volume in detecting patients with acute venous thromboembolism. J Clin Lab Anal 34(1):e23010. https://doi.org/10.1002/jcla.23010CrossRefPubMed

22.

Zahorec R (2021) Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy 122(7):474–488. https://doi.org/10.4149/bll_2021_078CrossRefPubMed

23.

Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T et al (2014) Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 23(7):1204–1212. https://doi.org/10.1158/1055-9965.EPI-14-0146CrossRefPubMed

24.

Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J et al (2014) Prognostic value of PLR in various cancers: a meta-analysis. PLoS ONE 9(6):e101119. https://doi.org/10.1371/journal.pone.0101119CrossRefPubMedPubMedCentral

25.

Wang H, Ding Y, Li N, Wu L, Gao Y, Xiao C et al (2020) Prognostic value of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in Stage IV Advanced Gastric Cancer. Front Oncol 10:841. https://doi.org/10.3389/fonc.2020.00841CrossRefPubMedPubMedCentral

26.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544CrossRefPubMed

27.

Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P et al (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8(2):15. https://doi.org/10.1038/s41408-018-0054-yCrossRefPubMedPubMedCentral

28.

Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90(8):1128–1132PubMed

29.

Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E et al (2012) Development and validation of an International Prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128–5133 quiz 5252. https://doi.org/10.1182/blood-2012-07-444067CrossRefPubMed

30.

Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901. https://doi.org/10.1182/blood-2008-07-170449CrossRefPubMed

31.

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061. https://doi.org/10.1016/S0140-6736(05)71142-9CrossRefPubMed

32.

Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL (2010) Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. J Mol Diagn 12(1):58–64. https://doi.org/10.2353/jmoldx.2010.090068CrossRefPubMedPubMedCentral

33.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8CrossRefPubMed

34.

Beltran BE, Aguilar C, Quiñones P, Morales D, Chavez JC, Sotomayor EM, Castillo JJ (2016) The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma 57(1):58–62. https://doi.org/10.3109/10428194.2015.1045897CrossRefPubMed

35.

Stefaniuk P, Szymczyk A, Podhorecka M (2020) The neutrophil to lymphocyte and lymphocyte to Monocyte Ratios as New Prognostic factors in hematological malignancies - A Narrative Review. Cancer Manag Res 12:2961–2977. https://doi.org/10.2147/CMAR.S245928CrossRefPubMedPubMedCentral

36.

Otasevic V, Mihaljevic B, Milic N, Stanisavljevic D, Vukovic V, Tomic K et al (2022) Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thromb J 20(1):20. https://doi.org/10.1186/s12959-022-00381-3CrossRefPubMedPubMedCentral

37.

Hu C, Zhao B, Ye Q, Zou J, Li X, Wu H (2023) The diagnostic value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for deep venous thrombosis: a systematic review and Meta-analysis. Clin Appl Thromb Hemost 29:10760296231187392. https://doi.org/10.1177/10760296231187392CrossRefPubMedPubMedCentral

38.

Artoni A, Abbattista M, Bucciarelli P, Gianniello F, Scalambrino E, Pappalardo E et al (2018) Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio as risk factors for venous thrombosis. Clin Appl Thromb Hemost 24(5):808–814. https://doi.org/10.1177/1076029617733039CrossRefPubMed

39.

Lucijanic M, Cicic D, Stoos-Veic T, Pejsa V, Lucijanic J, Fazlic Dzankic A et al (2018) Elevated neutrophil-to-lymphocyte-ratio and platelet-to-lymphocyte ratio in myelofibrosis: inflammatory biomarkers or representatives of Myeloproliferation itself? Anticancer Res 38(5):3157–3163. https://doi.org/10.21873/anticanres.12579CrossRefPubMed

40.

Kwon SS, Yoon SY, Jeong SY, Lee MY, Kim KH, Lee N, Won JH (2022) Neutrophil-lymphocyte ratio and carotid plaque burden in patients with essential thrombocythemia and polycythemia vera. Nutr Metab Cardiovasc Dis 32(8):1913–1916. https://doi.org/10.1016/j.numecd.2022.04.013CrossRefPubMed

41.

Carobbio A, Vannucchi AM, De Stefano V, Masciulli A, Guglielmelli P, Loscocco GG et al (2022) Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J 12(2):28. https://doi.org/10.1038/s41408-022-00625-5CrossRefPubMedPubMedCentral

42.

Zhou D, Chen W, Cheng H, Qiao JL, Zhu LL, Li ZY, Xu KL (2018) Clinico-hematological profile and thrombotic/hemorrhagic events in 150 Chinese patients with essential thrombocythemia. Leuk Res 69:1–6. https://doi.org/10.1016/j.leukres.2018.03.013CrossRefPubMed

43.

Kocak MZ, Dağlı M, Ünlü A (2017) The ratio of platelet/lymphocyte, the ratio of neutrophil/lymphocyte and some haemogram parameters related to thrombosis in essential thrombocytosis and polycythaemia vera. Biomed Res 28(7):3036–3039

44.

Hacibekiroglu T, Akinci S, Basturk A, inal B, Guney T, Bakanay SM, Dilek I (2015) Evaluation of inflammation parameters in Philadelphia negative chronic myeloproliferative neoplasia patients. Asian Pac J Cancer Prev 16(13):5159–5162. https://doi.org/10.7314/APJCP.2015.16.13.5159CrossRefPubMed

45.

Brabrand M, Frederiksen H (2020) Risks of solid and lymphoid malignancies in patients with myeloproliferative neoplasms: clinical implications. Cancers (Basel) 12(10):3061. https://doi.org/10.3390/cancers12103061CrossRefPubMed

46.

Moliterno AR, Ginzburg YZ, Hoffman R (2021) Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. Blood 137(9):1145–1153. https://doi.org/10.1182/blood.2020008043CrossRefPubMedPubMedCentral

47.

Cumbo C, Anelli L, Zagaria A, Coccaro N, Tarantini F, Specchia G et al (2022) Second Cancer Onset in Myeloproliferative neoplasms: what, when, why? Int J Mol Sci 23(6):3177. https://doi.org/10.3390/ijms23063177CrossRefPubMedPubMedCentral

48.

De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N et al (2020) Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. Blood 135(5):381–386. https://doi.org/10.1182/blood.2019002614CrossRefPubMed

49.

Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E et al (2011) Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 96(3):441–449. https://doi.org/10.3324/haematol.2010.033506CrossRefPubMed

50.

Koster KL, Messerich NM, Volken T, Cogliatti S, Lehmann T, Graf L et al (2023) Prognostic significance of the myelodysplastic syndrome-specific Comorbidity Index (MDS-CI) in patients with myelofibrosis: a retrospective study. Cancers (Basel) 15(19):4698. https://doi.org/10.3390/cancers15194698CrossRefPubMed

51.

Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R et al (2007) The haematocrit and platelet target in polycythemia vera. Br J Haematol 136(2):249–259. https://doi.org/10.1111/j.1365-2141.2006.06430.xCrossRefPubMed

52.

Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R et al (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109(6):2310–2313. https://doi.org/10.1182/blood-2006-09-046342CrossRefPubMed

53.

Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R et al (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109(6):2446–2452. https://doi.org/10.1182/blood-2006-08-042515CrossRefPubMed

54.

Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A et al (2023) A globally applicable triple A risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. Am J Hematol 98(12):1829–1837. https://doi.org/10.1002/ajh.27079CrossRefPubMed

55.

Noris P, Melazzini F, Balduini CL (2016) New roles for mean platelet volume measurement in the clinical practice? Platelets 27(7):607–612. https://doi.org/10.1080/09537104.2016.1224828CrossRefPubMed

56.

Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T (2007) V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 35(5):702–711. https://doi.org/10.1016/j.exphem.2007.01.053CrossRefPubMed

57.

Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18. https://doi.org/10.1186/s13045-016-0242-9CrossRefPubMedPubMedCentral

58.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J et al (2009) JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 37(10):1186–1193e7. https://doi.org/10.1016/j.exphem.2009.07.005CrossRefPubMed

59.

Lekovic D, Bogdanovic A, Sobas M, Arsenovic I, Smiljanic M, Ivanovic J et al (2023) Easily Applicable Predictive score for Differential diagnosis of Prefibrotic primary myelofibrosis from essential thrombocythemia. Cancers (Basel 15(16):4180. https://doi.org/10.3390/cancers15164180CrossRefPubMed

60.

Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A et al (2022) Myeloproliferative neoplasms, Version 3.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 20(9):1033–1062. https://doi.org/10.6004/jnccn.2022.0046CrossRefPubMed

Title: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms
Authors: Mirjana Cvetković
Isidora Arsenović
Mihailo Smiljanić
Marta Sobas
Andrija Bogdanović
Danijela Leković
Publication date: 27-09-2024
Publisher: Springer Berlin Heidelberg
Keywords: Thrombosis
Primary Myelofibrosis
Primary Myelofibrosis
Venous Thrombosis
Venous Thrombosis
Published in: Annals of Hematology
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-06023-0

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

12-09-2024
Type 1 Diabetes
News

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

12-09-2024
Obesity
News

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

12-09-2024
Type 2 Diabetes
News

Liraglutide reduces BMI for young children with obesity

11-09-2024
Pediatric Obesity
News

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024
Myocardial Infarction
News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Antihypertensives: more effective at morning or night?

02-09-2024
Hypertension
News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024
Type 2 Diabetes
News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms

Abstract

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Please log in to get access to this content

EASD 2024

2024 ESC Congress